Efficacy of thymoquinone in the treatment of experimental lipopolysaccharide-induced acute lung injury

Creative Commons License

Colak M., Kalemci S., ÖZGEN ALPAYDIN A., KARAÇAM V., Meteoglu I., YILMAZ O., ...More

KARDIOCHIRURGIA I TORAKOCHIRURGIA POLSKA-POLISH JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY, vol.17, no.2, pp.65-69, 2020 (ESCI) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 17 Issue: 2
  • Publication Date: 2020
  • Doi Number: 10.5114/kitp.2020.97259
  • Journal Name: KARDIOCHIRURGIA I TORAKOCHIRURGIA POLSKA-POLISH JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY
  • Journal Indexes: Emerging Sources Citation Index (ESCI), Scopus, Academic Search Premier, Directory of Open Access Journals
  • Page Numbers: pp.65-69
  • Keywords: acute lung injury, thymoquinone, lipopolysaccharide, ACUTE RESPIRATORY-DISTRESS, EUROPEAN CONSENSUS CONFERENCE, NIGELLA-SATIVA, RELEVANT OUTCOMES, DEFINITIONS, PREVENTION, MECHANISMS, MODEL, ARDS
  • Dokuz Eylül University Affiliated: Yes

Abstract

Introduction: Acute lung injury (ALI) and acute respiratory distress syndrome (ARDS) are acute onset syndromes affecting the lungs, which develop for several reasons and are characterized by hypoxemia and diffuse lung infiltration. The activity of thymoquinone (TO) is known in acute lung injury. It is considered that it could be effective in ALI/ARDS treatment by ensuring possible COX-2 inhibition.